Deals In Depth: September 2013
Executive Summary
Biogen and Isis teamed up for the fourth time in a new deal worth $450 million, focused on CNS disorders; Stryker gained robotic-assisted surgery expertise in its $1.4 billion acquisition of MAKO Surgical. Biopharma financing more than doubled in September compared with the previous month, reaching $1.7 billion and boosted by KV Pharma’s $375 million offering; device fundraising also increased, to $205 million, driven by early-stage venture rounds.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.